RZLT - NASDAQ
Rezolute, Inc.
$4.58
+14%Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
At a Glance
Live SnapshotRezolute, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Rezolute, Inc. Cash Flow Statement
RZLT • NASDAQ
| Rezolute, Inc. Cash Flow Statement | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Jun 2014 | Jun 2013 | Jun 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||
-74.4M | -68.5M | -51.8M | -41.1M | -20.9M | -20.3M | -30.4M | -29.9M | -20.3M | -14.9M | -11.4M | -9.7M | -6.7M | -49.3K | |
31K | 36K | 30K | 13K | 13K | 18K | 49K | 1.1M | 1.1M | 751.3K | 134.1K | 11.3K | 295.0 | 221.0 | |
0.0 | 0.0 | -1.4M | 0.0 | -1.8M | 102K | -17K | 2.9M | 0.0 | 0.0 | 756.3K | 4.6M | 0.0 | 0.0 | |
7.1M | 7.4M | 7.3M | 3.7M | 4M | 3.3M | 2.6M | 5.1M | 6M | 3.8M | 2.8M | 1.1M | 3.7M | 0.0 | |
-1.9M | 595K | 352K | -1.6M | 384K | 222K | 4.1M | 5.6M | 1.2K | 53.2K | 166.1K | 404.6K | 456.2K | 9.8K | |
47K | 3.1M | 1M | -642K | -2.1M | -7.5M | 8.4M | 1M | -155.4K | -119.2K | 380.2K | 488.4K | 955.5K | -1.1K | |
-69.1M | -57.4M | -44.5M | -39.6M | -20.4M | -24.2M | -15.3M | -14.1M | -13.3M | -10.5M | -7.1M | -3.2M | -1.6M | -40.4K | |
INVESTING ACTIVITIES | ||||||||||||||
(0.0) | (0.0) | -153K | (0.0) | (0.0) | (0.0) | -47K | -5.8K | -407.9K | -2.1M | -3.2M | -70K | -11.7K | -2K | |
(0.0) | (0.0) | (101.5M) | (0.0) | (0.0) | (0.0) | (278K) | (1.6M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-128.1M | -66.4M | -107.3M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
113.6M | 115.1M | 6M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | -101.5M | 0.0 | 0.0 | 0.0 | 278.0 | 1.7M | 212.5K | 637.7K | -450.2K | -760.2K | 196.8K | 0.0 | |
-14.5M | (48.7M) | -101.5M | (0.0) | (0.0) | (0.0) | (231K) | (1.7M) | -195.4K | -1.5M | -3.6M | -830.2K | (185.1K) | -2K | |
FINANCING ACTIVITIES | ||||||||||||||
107.3M | 49M | 12.3M | 122.8M | 41M | 24.1M | 0.0 | 4.5M | 14.6M | 5.4M | 11.2M | 8.9M | 0.0 | 10.5K | |
0.0 | 0.0 | 0.0 | -16M | 15M | 0.0 | 0.0 | 5.3M | -23.1K | -93.9K | -67.9K | 2.6M | 1.6M | 0.0 | |
0.0 | 14M | -759K | 31.4M | -4.5M | -1.5M | 0.0 | -299.3K | -683.2K | -890.4K | -1.1M | -1.6M | -157.5K | -2M | |
107.3M | 63M | 11.6M | 149M | 51.5M | 22.6M | 25M | 9.5M | 13.9M | 10.7M | 10M | 9.9M | 1.4M | 10.5K | |
CASH FLOW SUMMARY | ||||||||||||||
23.7M | 54.4M | -134.4M | 109.4M | 31.1M | -1.6M | 9.9M | -2.8M | 424.5K | -1.2M | -655.8K | 5.9M | -25.4K | -31.9K | |
70.4M | 16M | 150.4M | 41M | 10M | 11.6M | 1.6M | 4.5M | 4.1M | 5.3M | 5.9M | 527.0 | 25.9K | 37K | |
94.1M | 70.4M | 16M | 150.4M | 41M | 10M | 11.6M | 1.6M | 4.5M | 4.1M | 5.3M | 5.9M | 527.0 | 5.1K | |
-69.1M | -57.4M | -44.6M | -39.6M | -20.4M | -24.2M | -15.4M | -14.1M | -13.7M | -12.6M | -10.2M | -3.2M | -1.6M | -42.4K |
SEC Filings
RZLT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 02, 2026 | June 02, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 04, 2026 | May 01, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 24, 2026 | March 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 12, 2026 | February 12, 2026 | 2026 | |
10-Q 10-Q 2025 Q4 Q4 | February 12, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | January 07, 2026 | January 07, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 21, 2025 | November 19, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 12, 2025 | November 10, 2025 | 2025 |
Related Guides
Continue your RZLT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.